Abbott (ABT) Gets FDA Nod For New Troponin-I Blood Test
Zacks Investment Research | Oct 01, 2019 09:48PM ET
Abbott Laboratories (NYSE:ABT) recently attained the FDA approval for its ARCHITECT STAT High Sensitivity Troponin-I blood test. This is one of the most meticulously-researched troponin diagnostic tests, which can now be utilized to diagnose heart attacks in a swifter and more accurate method than contemporary troponin tests.
The integration of Abbott's high sensitivity troponin-I assay to the laboratory's diagnostic testing menu is a major stride forward in the company’s commitment toward detecting patients suspected of having a heart attack. Encouragingly, this FDA clearance is expected to boost its Diagnostics business segment.
More About the Blood Test
Abbott's High Sensitivity Troponin-I blood test is equipped to measure very low levels of troponin, allowing doctors to determine heart attack in patients within two to four hours of admission. Women are expected to particularly benefit from this new technology as they mostly have lower levels of troponin than men, which make them more susceptible to undiagnosed heart attacks with contemporary troponin tests.
This high-sensitivity assay has been proved to diagnose a heart attack earlier. This could help hospitals with swifter management of those diagnosed with a heart attack, as well as ensure safe and early discharge of patients, resulting in savings for the healthcare system.
With this FDA clearance, the blood test may be sold in the United States for use on Abbott's fully-automated ARCHITECT analyzer. The ARCHITECT STAT High Sensitivity Troponin-I outcomes should be used in combination with other diagnostic information such as electrocardiogram (ECG), clinical observations and information, and patient symptoms to help in the detection of heart attacks.
Market Prospects
The heart attack diagnostics market is projected to reach $15.4 billion by 2024, according to a new report by Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.